A Brief Review of Clinical Considerations for Healthcare Provider-Administered Cardiovascular Risk Modifying Medications
Article Sidebar
Main Article Content
Abstract
Abstract
Cardiovascular Disease (CVD) remains a major contributor to morbidity and mortality, with effective lipid management being essential in reducing Atherosclerotic Cardiovascular Disease (ASCVD) risk. While statins have long been the primary treatment, barriers such as intolerance, poor adherence, and clinical inertia often prevent patients from achieving optimal Low-Density Lipoprotein Cholesterol (LDL-C) levels. Despite the availability of alternative lipid-lowering therapies (LLTs), many patients still fail to meet recommended targets. The introduction of provider-administered LLTs, like inclisiran, presents a promising strategy to enhance adherence through in-office administration under a "buy-and-bill" model. This approach improves treatment continuity, reduces administrative hurdles, and may alleviate financial constraints, particularly for Medicare beneficiaries. Implementing this model successfully requires coordinated efforts, including provider education, infrastructure development, and streamlined reimbursement processes. As cardiovascular care continues to advance, provider-administered LLTs may play a critical role in improving patient outcomes and mitigating the burden of ASCVD.
Downloads
Article Details
Copyright (c) 2025 Ibrahim A, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics—2023 update: A report from the American Heart Association. Circulation. 2023;147(8):e93-e621. Available from: https://doi.org/10.1161/cir.0000000000001123
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. Available from: https://doi.org/10.1093/eurheartj/ehx144
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177-e232. Available from: https://doi.org/10.1161/cir.0000000000000677
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. Available from: https://doi.org/10.1093/eurheartj/ehz455
Ingersgaard MV, Helms Andersen T, Norgaard O, Grabowski D, Olesen K. Reasons for nonadherence to statins - a systematic review of reviews. Patient Prefer Adherence. 2020;14:675-91. Available from: https://doi.org/10.2147/ppa.s245365
Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1-9. Available from: https://doi.org/10.1001/jamacardio.2021.1810
Murrin S. States Could Do More To Oversee Spending and Contain Medicaid Costs for Specialty Drugs. U.S. Department of Health and Human Services Office of Inspector General; 2020. Report No.: OEI-03-17-00430. Available from: https://oig.hhs.gov/reports/all/2020/states-could-do-more-to-oversee-spending-and-contain-medicaid-costs-for-specialty-drugs/
Novartis Pharmaceuticals Corporation. LEQVIO. Prescribing Information. December 2021 [cited April 19, 2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
O'Riordan M. Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path. tctmd. January 17, 2022. Available from: https://www.tctmd.com/news/pricey-inclisiran-rolling-out-buy-and-bill-model-may-smooth-its-path
Fein AJ. Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs. [cited April 19, 2023]. Available from: https://www.drugchannels.net/2021/10/follow-vial-buy-and-bill-system-for.html
HDMA looks closely at 'buy and bill' in specialty pharma distribution. [cited 2023 July 14, 2023]. Available from: https://www.pharmaceuticalcommerce.com/view/hdma-looks-closely-at-buy-and-bill-in-specialty-pharma-distribution
How to Pay for Vaccines. [cited 2023 July 14, 2023]. Available from: https://www.cdc.gov/vaccines/adults/pay-for-vaccines.html
Muzumdar S, Waldman R, Wu R, Kelsey A. In-office administration associated with increased drug survival of ustekinumab for chronic plaque psoriasis when compared with self-administration: A single-institution retrospective chart review. J Am Acad Dermatol. 2023;88(5):1111-3. Available from: https://doi.org/10.1016/j.jaad.2019.10.041
Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic. J Clin Lipidol. 2023;17(1):73-7. Available from: https://doi.org/10.1016/j.jacl.2022.10.009
Panettieri RA, Chipps BE. So How Do I Implement Monoclonal Antibody Therapy in My Practice: The Financial Consequences? [cited 2023 July 14, 2023]. Available from: https://member.thoracic.org/about/newsroom/newsletters/coding-andbilling/2016/june/physician-administered-drugs.php
Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic. J Clin Lipidol. 2023;17(1):73-7. Available from: https://doi.org/10.1016/j.jacl.2022.10.009
Cavalier JS, Shah NP, Blazing MA. Why novel therapies in preventive cardiology may face a marathon, not a sprint. Circulation. 2023;148(11):859-61. Available from: https://doi.org/10.1161/circulationaha.122.063099
Specialty Drug Resource. Understanding specialty drug coverage and acquisition: A guide for HCPs and offices. 2022. Available from: https://www.specialtydrugresource.com/
Axene Health Partners. Physician Fee Schedules: How Do They Compare and What’s Next? [cited 2023 August 10, 2023]. Available from: https://axenehp.com/physician-fee-schedules-compare-whats-next/
HealthWell Foundation® website. [cited August 14, 2023]. Available from: https://www.healthwellfoundation.org/
Centers for Medicare & Medicaid Services. Billing and Coding: Complex Drug Administration Coding. [cited October 24, 2023].
Centers for Medicare & Medicaid Services. Billing of Temporary “C” HCPCS Codes by Non-Outpatient Prospective Payment System (Non-OPPS) Providers. 2006 [cited October 27, 2023].
MedPAC. Part B Drugs Payment Systems. August 10, 2023 [cited]. Available from: https://www.medpac.gov/wp-content/uploads/2022/10/MedPAC_Payment_Basics_23_PartB_FINAL_SEC.pdf
Medicaid and CHIP Payment and Access Commission. Provider payment under fee for service. [cited 2023 August 11, 2023]. Available from: https://www.macpac.gov/subtopic/provider-payment
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PL, Kastelein JJ. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-19. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1912387
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182-93. Available from: https://doi.org/10.1016/j.jacc.2020.12.058
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-418. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2022.07.006